| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Vincenzo Ostilio Palmieri | Q57427122 |
| Nicola Silvestris | Q87916808 | ||
| Riccardo Memeo | Q114138810 | ||
| Andrea Casadei Gardini | Q42838004 | ||
| Daniele Santini | Q37837892 | ||
| Oronzo Brunetti | Q39379387 | ||
| P2093 | author name string | Giuseppe Aprile | |
| Salvatore Pisconti | |||
| Mario Scartozzi | |||
| Patrizia Nardulli | |||
| Vito Longo | |||
| Antonio Gnoni | |||
| Antonella Licchetta | |||
| P2860 | cites work | Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy | Q26745516 |
| Current status and perspectives of immune-based therapies for hepatocellular carcinoma | Q26772326 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis | Q27489394 | ||
| Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors | Q29619686 | ||
| Chronically inflamed livers up-regulate expression of inhibitory B7 family members | Q30434304 | ||
| PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation | Q33569771 | ||
| A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma | Q33579629 | ||
| Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. | Q33614172 | ||
| Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors | Q33765767 | ||
| Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma | Q33868428 | ||
| PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine | Q33950150 | ||
| Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Q34327051 | ||
| A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. | Q34995738 | ||
| VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors | Q35064894 | ||
| Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. | Q51985394 | ||
| Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo. | Q53166613 | ||
| Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease | Q56902429 | ||
| Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge | Q57079517 | ||
| Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response | Q58802772 | ||
| Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy | Q61463001 | ||
| Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma | Q63641926 | ||
| Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma | Q64132234 | ||
| Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients | Q80480802 | ||
| Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas | Q81228401 | ||
| A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma | Q82079122 | ||
| VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells | Q82264553 | ||
| Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion | Q82449382 | ||
| Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation | Q83035499 | ||
| Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO | Q83060123 | ||
| The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients | Q87157814 | ||
| A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. | Q39922106 | ||
| Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection | Q42071282 | ||
| A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. | Q42989841 | ||
| Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells | Q44190750 | ||
| Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival | Q44332051 | ||
| A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer | Q44370683 | ||
| Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma | Q44517849 | ||
| Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma | Q45383999 | ||
| Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses | Q46725768 | ||
| T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. | Q46973633 | ||
| Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. | Q50856082 | ||
| Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. | Q50909590 | ||
| Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. | Q51808506 | ||
| CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice | Q35528287 | ||
| Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. | Q35567765 | ||
| Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy | Q35634179 | ||
| Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis | Q35660038 | ||
| Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation | Q35750826 | ||
| Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1) | Q36366414 | ||
| Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy | Q36378276 | ||
| Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety | Q36444510 | ||
| Helper T-cell identity and evolution of differential transcriptomes and epigenomes. | Q36623362 | ||
| Cytokine-induced killer cells promote antitumor immunity | Q36741617 | ||
| Peptide vaccines for hepatocellular carcinoma | Q36888010 | ||
| Immunological aspects of cancer chemotherapy | Q37039588 | ||
| Immunotherapeutic approaches to hepatocellular carcinoma treatment | Q37140685 | ||
| Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study | Q37404372 | ||
| Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. | Q37666058 | ||
| Management of hepatocellular carcinoma: beyond sorafenib. | Q37995523 | ||
| Medical therapies for hepatocellular carcinoma: a critical view of the evidence | Q38059437 | ||
| mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. | Q38071900 | ||
| Roles for chemokines in liver disease | Q38234487 | ||
| Metronomic chemotherapy from rationale to clinical studies: a dream or reality? | Q38346010 | ||
| Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? | Q38554626 | ||
| Immunological landscape and immunotherapy of hepatocellular carcinoma | Q38611895 | ||
| Immunotherapy in hepatocellular carcinoma: Primed to make a difference? | Q38625948 | ||
| Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma | Q38728953 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? | Q38835601 | ||
| GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice | Q38988024 | ||
| The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies | Q39535683 | ||
| Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma | Q39888328 | ||
| IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. | Q39895766 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| immunotherapy | Q1427096 | ||
| liver neoplasm | Q18558073 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 33897-33910 | |
| P577 | publication date | 2017-02-16 | |
| 2017-05-16 | |||
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Immunotherapeutic approaches for hepatocellular carcinoma | |
| P478 | volume | 8 |
| Q57300204 | 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12 |
| Q55312817 | A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor. |
| Q92733290 | Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma |
| Q56890138 | Characteristics of immune response to tumor-associated antigens and immune cell profile in hepatocellular carcinoma patients |
| Q93078271 | Etiology-Specific Analysis of Hepatocellular Carcinoma Transcriptome Reveals Genetic Dysregulation in Pathways Implicated in Immunotherapy Efficacy |
| Q54963955 | Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations. |
| Q90094702 | Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status |
| Q90398077 | Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model |
| Q59136533 | Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment |
| Q94942876 | Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation |
| Q55223567 | Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. |
| Q64086690 | The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response |
| Q57053754 | The Role of Angiogenesis in Hepatocellular Carcinoma |
| Q91791487 | The role of the innate immune system in the development and treatment of hepatocellular carcinoma |
Search more.